Long-term outcomes after Resolute zotarolimus-eluting stent implantation in patients with ST-segment elevation acute myocardial infarction: insights from the RESOLUTE All Corners Trial and the RESOLUTE Global Clinical Trial Program

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F16%3AN0000006" target="_blank" >RIV/00064173:_____/16:N0000006 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/16:43912917

Výsledek na webu

<a href="http://dx.doi.org/10.4244/EIJV12I10A199" target="_blank" >http://dx.doi.org/10.4244/EIJV12I10A199</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4244/EIJV12I10A199" target="_blank" >10.4244/EIJV12I10A199</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Long-term outcomes after Resolute zotarolimus-eluting stent implantation in patients with ST-segment elevation acute myocardial infarction: insights from the RESOLUTE All Corners Trial and the RESOLUTE Global Clinical Trial Program

Popis výsledku v původním jazyce

Aims: We examined long-term outcomes after implantation of the Resolute zotarolimus-eluting stent (R-ZES) in ST-segment elevation acute myocardial infarction (STEMI) patients. Methods and results: We compared long-term outcomes of STEMI patients undergoing primary angio-plasty <12 hours from syniptom onset who were randomised to the R-ZES (n=122) or the everolimuseluting stent (EES, n=158) in the RESOLUTE All Comers Trial after propensity score adjustment. The five-year cumulative incidence of target lesion failure (TLF) was 7.6% versus 10.4% among patients treated with R-ZES versus EES, respectively, (adjusted p=0.304), and comprised clinically driven target lesion revascularisation (TLR, 2.5% versus 2.0%, adjusted p=0.766) and cardiac death/target vessel MI (5.1% versus 9.1%, adjusted p=0.123). The five-year cumulative incidence of stent thrombosis was 0.8% for R-ZES patients versus 1.3% for EES patients (adjusted p=0.868). In the RESOLUTE Global Clinical Trial Program, excluding RESOLUTE All Comers, the three-year cumulative incidence of TLF with R-ZES was 9.8% and comprised 7.0% clinically driven TLR and 4.5% cardiac death/target vessel MI. Conclusions: Patients with STEMI who received R-ZES had excellent long-term clinical outcomes which were similar to those of patients who received EES.

Název v anglickém jazyce

Long-term outcomes after Resolute zotarolimus-eluting stent implantation in patients with ST-segment elevation acute myocardial infarction: insights from the RESOLUTE All Corners Trial and the RESOLUTE Global Clinical Trial Program

Popis výsledku anglicky

Aims: We examined long-term outcomes after implantation of the Resolute zotarolimus-eluting stent (R-ZES) in ST-segment elevation acute myocardial infarction (STEMI) patients. Methods and results: We compared long-term outcomes of STEMI patients undergoing primary angio-plasty <12 hours from syniptom onset who were randomised to the R-ZES (n=122) or the everolimuseluting stent (EES, n=158) in the RESOLUTE All Comers Trial after propensity score adjustment. The five-year cumulative incidence of target lesion failure (TLF) was 7.6% versus 10.4% among patients treated with R-ZES versus EES, respectively, (adjusted p=0.304), and comprised clinically driven target lesion revascularisation (TLR, 2.5% versus 2.0%, adjusted p=0.766) and cardiac death/target vessel MI (5.1% versus 9.1%, adjusted p=0.123). The five-year cumulative incidence of stent thrombosis was 0.8% for R-ZES patients versus 1.3% for EES patients (adjusted p=0.868). In the RESOLUTE Global Clinical Trial Program, excluding RESOLUTE All Comers, the three-year cumulative incidence of TLF with R-ZES was 9.8% and comprised 7.0% clinically driven TLR and 4.5% cardiac death/target vessel MI. Conclusions: Patients with STEMI who received R-ZES had excellent long-term clinical outcomes which were similar to those of patients who received EES.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

EuroIntervention

ISSN

1774-024X

e-ISSN

—

Svazek periodika

12

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

FR - Francouzská republika

Počet stran výsledku

8

Strana od-do

1207-1214

Kód UT WoS článku

000390981500004

EID výsledku v databázi Scopus

2-s2.0-85001889553